Société de Therapeutique Marocaine Valuation

Q: What is the Fair Price of SOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SOT (MAD948) is trading above our estimate of [[fair value]] (MAD68.89)

Is SOT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOT (MAD948) is trading above our estimate of fair value (MAD68.89)

Significantly Below Fair Value: SOT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOT?

Key metric: As SOT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SOT. This is calculated by dividing SOT's market cap by their current earnings.
What is SOT's PE Ratio?
PE Ratio	24.3x
Earnings	د.م280.52m
Market Cap	د.م6.83b

SOT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	15.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does SOT's PE Ratio compare to its peers?

The above table shows the PE ratio for SOT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.9x
PRO Societe de Promotion Pharmaceutique du Maghreb	16.2x	n/a	د.م920.0m
A214370 Caregen	31.8x	13.6%	₩1.0t
A003090 Daewoong	7.4x	n/a	₩871.0b
RENATA Renata	20.3x	n/a	৳73.4b
SOT Société de Therapeutique Marocaine	24.3x	n/a	د.م6.8b

Price-To-Earnings vs Peers: SOT is expensive based on its Price-To-Earnings Ratio (24.3x) compared to the peer average (18.8x).

Price to Earnings Ratio vs Industry

How does SOT's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: SOT is expensive based on its Price-To-Earnings Ratio (24.3x) compared to the African Pharmaceuticals industry average (10.1x).

Price to Earnings Ratio vs Fair Ratio

What is SOT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	24.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SOT's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.